Show simple item record

dc.contributor.authorHussain, SA
dc.contributor.authorBirtle, A
dc.contributor.authorCrabb, S
dc.contributor.authorHuddart, R
dc.contributor.authorSmall, D
dc.contributor.authorSummerhayes, M
dc.contributor.authorJones, R
dc.contributor.authorProtheroe, A
dc.date.accessioned2019-06-24T08:59:24Z
dc.date.issued2018-12
dc.identifier.citationEuropean urology oncology, 2018, 1 (6), pp. 486 - 500
dc.identifier.issn2588-9311
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3271
dc.identifier.eissn2588-9311
dc.identifier.doi10.1016/j.euo.2018.05.011
dc.description.abstractContext A number of PD-1/PD-L1 inhibitors have recently been approved for use in patients with locally advanced or metastatic urothelial carcinoma (UC) on the basis of results from several clinical trials.Objective To review the evidence from these trials and consider what it means for the use of these drugs in first-line and post-platinum settings in real-life clinical practice.Evidence acquisition PubMed was searched for full reports of clinical trials of single-agent PD-1/PD-L1 inhibitors in advanced UC. Twelve publications were included.Evidence synthesis Responses to PD-1/PD-L1 inhibitors appear to be durable but are only achieved in 17-26% of patients. These drugs offer different toxicity and efficacy profiles to standard chemotherapy regimens. This should be considered when choosing a treatment strategy for each patient.Conclusions PD-1/PD-L1 inhibitors represent a major step forward in the management of advanced UC, although several questions remain regarding their optimal use in routine clinical practice. A validated predictive biomarker of response is yet to be defined, and this is perhaps the most significant unmet need for currently available drugs.Patient summary We reviewed the results from clinical trials that investigated how well certain types of anticancer drugs called PD-1/PD-L1 inhibitors worked in patients with bladder cancer. We found that more research is required to identify (1) the factors that might predict which patients with bladder cancer will respond to PD-1/PD-L1 inhibitors and (2) the optimum duration of treatment with these drugs.
dc.formatPrint-Electronic
dc.format.extent486 - 500
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectUrologic Neoplasms
dc.subjectCisplatin
dc.subjectAntibodies, Monoclonal
dc.subjectImmunotherapy
dc.subjectUrinary Bladder Neoplasms
dc.subjectClinical Trials as Topic
dc.subjectAntibodies, Monoclonal, Humanized
dc.subjectProgrammed Cell Death 1 Receptor
dc.subjectAntineoplastic Agents, Immunological
dc.subjectIpilimumab
dc.subjectB7-H1 Antigen
dc.titleFrom Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
dc.typeJournal Article
dcterms.dateAccepted2018-05-30
rioxxterms.versionofrecord10.1016/j.euo.2018.05.011
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2018-12
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEuropean urology oncology
pubs.issue6
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart)
pubs.publication-statusPublished
pubs.volume1
pubs.embargo.termsNot known
icr.researchteamClinical Academic Radiotherapy (Huddart)en_US
dc.contributor.icrauthorHuddart, Roberten


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0